3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2/3
1
Status
Completed
8
Active not recruiting
4
Terminated
3
Not yet recruiting
3
Unknown
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
3
Head & Neck
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Colorectal Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Ameloblastoma
1
Interventions
Bevacizumab
37
Oxaliplatin
17
Capecitabine
17
Irinotecan
15
Leucovorin
13
HMPL-013
12
Fluorouracil
12
Cetuximab
11
trifluridine tipiracil drug combination
7
irinotecan sucrosofate
6
tipiracil
5
Trifluridine
5
Specimen Handling
5
Drug Therapy
5
tislelizumab
4
Standard of Care
4
Mitomycin
4
Magnetic Resonance Spectroscopy
4
Injections
4
Folfox protocol
4
trametinib
3
toripalimab
3
pembrolizumab
3
Nivolumab
3
IFL protocol
3
Colonoscopy
3
Blood Specimen Collection
3
Biopsy
3
zanidatamab
2
sotorasib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Colorectal Neoplasms
×
trametinib
×
Clear all
NCT07468071
2026-04-02
KontRASt-R
Novartis
Phase 1/2
Not yet recruiting
40 enrolled
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05275374
2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2
Not yet recruiting
221 enrolled